PD-L1 22C3 Immunohistochemistry Test: Advanced Cancer Biomarker Analysis
Understanding the PD-L1 22C3 Immunohistochemistry Test
The PD-L1 22C3 Immunohistochemistry Test represents a groundbreaking advancement in precision oncology, providing critical insights into cancer biology and treatment response. This sophisticated diagnostic procedure specifically detects and quantifies the expression of programmed death-ligand 1 (PD-L1) protein on cancer cells using the validated 22C3 antibody clone. As immunotherapy continues to revolutionize cancer care, this test has become an essential component of modern oncology practice, helping clinicians make informed decisions about immune checkpoint inhibitor therapies.
What Does the Test Measure?
The PD-L1 22C3 Immunohistochemistry Test precisely measures:
- PD-L1 protein expression levels on tumor cell membranes
- Tumor proportion score (TPS) indicating percentage of PD-L1 positive tumor cells
- Combined positive score (CPS) incorporating immune cell staining
- Pattern and intensity of PD-L1 staining in tumor microenvironment
Who Should Consider This Test?
This advanced biomarker testing is particularly recommended for patients with:
- Non-small cell lung cancer (NSCLC) considering immunotherapy
- Head and neck squamous cell carcinoma
- Esophageal cancer patients evaluating treatment options
- Cervical cancer cases requiring biomarker assessment
- Gastric cancer patients exploring targeted therapies
- Other solid tumors where immunotherapy may be beneficial
Clinical Indications and Symptoms
Patients experiencing persistent symptoms such as unexplained weight loss, chronic cough, difficulty swallowing, or abnormal bleeding should discuss PD-L1 testing with their oncologist. Early biomarker assessment can significantly impact treatment planning and outcomes.
Benefits of PD-L1 22C3 Testing
- Personalized Treatment Planning: Identifies patients most likely to respond to immunotherapy
- Improved Outcomes: Helps avoid ineffective treatments and associated side effects
- Cost-Effective Care: Directs resources toward therapies with highest probability of success
- Comprehensive Analysis: Provides detailed biomarker information for clinical decision-making
- Rapid Results: Quick turnaround time enables timely treatment initiation
Understanding Your Test Results
Your PD-L1 22C3 test results will include detailed information about:
- Tumor Proportion Score (TPS): Percentage of tumor cells expressing PD-L1
- Cut-off Values: Specific thresholds for treatment eligibility
- Staining Patterns: Distribution and intensity of PD-L1 expression
- Clinical Interpretation: Expert analysis correlating results with treatment options
Results are typically categorized as:
- High Expression: May indicate better response to immunotherapy
- Low Expression: May suggest alternative treatment approaches
- Negative: Limited PD-L1 expression detected
Test Pricing Information
| Test Name | Regular Price | Discount Price |
|---|---|---|
| PD-L1 22C3 Immunohistochemistry Test | $456 USD | $410 USD |
Turnaround Time
- Sample Acceptance: Daily by 6 PM
- Tissue Block Results: 5 days
- Tissue Biopsy Results: 5 days
- Complex Tissue Samples: 7 days
Sample Requirements and Preparation
For accurate PD-L1 22C3 testing, please provide:
- Tumor tissue preserved in 10% formal-saline solution
- Formalin-fixed paraffin-embedded tissue blocks
- Ship samples at room temperature with proper packaging
- Complete histopathology report copy
- Detailed biopsy site information
- Comprehensive clinical history
Nationwide Testing Availability
General Genetics Corporation provides comprehensive PD-L1 22C3 testing services across the United States. Our state-of-the-art laboratories serve patients in major metropolitan areas including:
- New York City and surrounding regions
- Los Angeles and Southern California
- Chicago and Midwest locations
- Houston and Texas medical centers
- Miami and Florida healthcare facilities
- Boston and New England area hospitals
Book Your PD-L1 22C3 Test Today
Take the next step in your cancer treatment journey with comprehensive biomarker testing. Our expert team is ready to assist you with scheduling, sample collection guidance, and result interpretation.
Call or WhatsApp: +1(267) 388-9828
Schedule your PD-L1 22C3 Immunohistochemistry Test today and gain valuable insights for your personalized cancer treatment plan. Our dedicated oncology specialists are available to answer your questions and guide you through the testing process.
